University of York scientists discover why some tumors are resistant to radiotherapy

July 24, 2015

Scientists at the University of York believe they have identified how some tiny regulatory molecules in cells can make prostate cancers resistant to radiotherapy.

It is hoped that this new development could pave the way for more effective treatments - allowing a lower dose of radiotherapy to be used while prolonging the lives of thousands of men.

Prostate cancer is the most commonly diagnosed form of male cancer in the UK and kills more than 11,000 men every year.

In the latest studies, published in European Urology and the British Journal of Cancer, scientists in The YCR Cancer Research Unit in the Department of Biology at York have shown a direct link between these tiny molecules - known as micro-RNAs - and resistance to radiotherapy.

Every cell has hundreds of micro-RNAs, whose function is to control the expression of genes.

Once regarded as "junk" by scientists, they are now considered vital for the organisation of the various tissues in the body, instructing genes when and where to be active.

The York team have now shown that they are the switch which enables cells to react very rapidly to changes in their environment, such as that provided by cancer treatments.

Previous research has revealed that all prostate cancers contain at least four different cell types, including the cancer stem cells which resist most current treatments.

By looking at the micro-RNAs present in each of the cell types individually, the researchers found that some micro-RNAs acted in a positive manner, switching off genes which could make the stem cells susceptible to radiotherapy, whilst other micro-RNAs were not expressed in the resistant stem cells, permitting the expression of resistance genes.

By manipulating the levels of these critical micro-RNAs in the clinic, scientists say it should be possible to kill greater numbers of cancer stem cells than ever before, reducing the 30% of prostate cancer patients whose tumours recur after radiotherapy.

Professor Norman Maitland, of The YCR Cancer Research Unit, said prostate cancer is diagnosed in about 42,000 men every year in the UK. Of those men about a third will get radiotherapy, and of those, about a third will fail on radiotherapy.

"Doctors don't know which patients are going to relapse - and the reason they relapse is probably because the radiotherapy is not focussed on the stem cell, it is focused on the whole tumour.

"We think that by exploiting this new knowledge we can make radiotherapy more effective. What is the impact? We believe it could extend the lifetime of these men. It could also allow a lower dose of radiotherapy to be used and that's really what we are testing at the moment.

"Now we have a handle on why stem cells cause men to relapse after radiotherapy, this will be the bridge to transforming that into a treatment and making radiotherapy better."

The research used tissues from prostate cancer patients, generously donated for this purpose via a Hull-York Medical School cooperation with Mr Matt Simms at Castle Hill Hospital in Hull.
-end-
The analysis was carried out by Dr Jayant Rane, as part of an EU-funded international consortium (PRONEST), in collaboration with Professor Tapio Visakorpi (University of Tampere, Finland), and Finnish bioinformaticians Antti Ylipaa and Professor Matti Nykter.

University of York

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.